Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2024-04-17 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION REGISTRATION AND COMPLETION OF THE PUBLIC ISSUANCE OF THE 2024 FIRST TRANCHE CORPORATE BONDS IN THE PRC
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the registration and completion of a public issuance of corporate bonds by a subsidiary of the company. It references regulatory approval from the China Securities Regulatory Commission and details the issuance size, terms, and use of proceeds. The document is relatively short (3215 characters) and serves as an update on financing activities rather than a full financial report or detailed presentation. It does not contain financial statements or detailed analysis but focuses on capital raising and bond issuance. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-04-17 English
CONTINUING CONNECTED TRANSACTIONS THE IT SERVICES PROCUREMENT FRAMEWORK AGREEMENT 2024
Regulatory Filings Classification · 95% confidence The document is an announcement from a Hong Kong listed company regarding the entering into of a continuing connected transaction framework agreement for IT services procurement. It details the terms, parties, historical amounts, annual caps, and compliance with the Listing Rules. The document is an announcement of a transaction agreement and not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the transaction. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a connected transaction under the Listing Rules, which does not fit into more specific categories like Capital/Financing Update or M&A Activity. The document length and detail confirm it is not a brief notice or a proxy statement. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-12 English
ANNOUNCEMENT RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE THREE MONTHS ENDED 31 MARCH 2024
Earnings Release Classification · 95% confidence The document is an announcement of a results estimate for the three months ended 31 March 2024 by Dong-E-E-Jiao, which is a subsidiary of the Company. It provides estimated net profit and earnings per share figures, but explicitly states that the results estimate has not been audited or reviewed and that the detailed quarterly report will be published later. The document is relatively short (5648 characters) and serves as a preliminary earnings estimate rather than a full financial report. It does not contain actual financial statements or comprehensive financial data, but rather a forecast and cautionary statement. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results or estimates with key highlights only. Q1 2024
2024-04-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 March 2024. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other share-related movements. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes specific stock code and share counts. It is a regulatory filing related to share capital movements and share options, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data on share movements. The document fits the category of Regulatory Filings (RNS) as it is a compliance document reporting share capital movements under exchange rules, without being a financial report or announcement of voting results or capital changes like new share issues or buybacks. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-02 English
Final Dividend for the Year Ended 31 December 2023
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Final Dividend for the Year Ended 31 December 2023' and contains detailed information about the dividend amount, currency options, important dates such as ex-dividend date, record date, payment date, and shareholder approval date. It also includes information about the share registrar and withholding tax. The document is an announcement specifically about the dividend amount and related logistics, not a full financial report or annual report. The length is 3283 characters, which is relatively short and focused solely on dividend details. Therefore, it fits the category of 'Notice of Dividend Amount' (DIV).
2024-03-26 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023' and contains detailed audited consolidated financial statements including profit or loss, comprehensive income, financial position, and notes to the consolidated financial statements. It includes extensive financial data for the full fiscal year ending December 31, 2023, and comparative figures for prior years. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with a comprehensive yearly report covering company activity and full financial performance, which matches the definition of an Annual Report (10-K). There is no indication that this is merely an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the document should be classified as an Annual Report (10-K). FY 2023
2024-03-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.